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Ectoparasites or epidermal parasites are responsible for a
heterogeneous group of infections of the external layer of
the skin. Scabies and pediculosis (capitis, corporis, and pubis)
are among the most common (despite the re-emergence of
diseases such as that caused by Pyemotes ventricosus and bed
bug infections) and share well-known features [1–3]: (i)
worldwide prevalence (involving millions of people annually);
(ii) parasites inducing skin lesions directly, such as with urti-
carial papules, and indirectly as a result of itching and hyper-
sensitivity to parasites, thus leading to a genuine nuisance
and sometimes daily nightmares or, in some cases, skin
superinfection; and (iii) treatment based on good entomolog-
ical knowledge of the parasite and practical considerations
(for example, most available treatments do not act on eggs
and should be repeated, depending on the life cycle of the
parasites [4]).
With this special issue of CMI, we provide an overview of
four major points that affect knowledge and/or management
of scabies and pediculosis for infectious disease specialists,
microbiologists, and dermatologists, as well as general practi-
tioners and healthcare workers. This issue is more than wel-
come, as scabies and pediculosis (and ectoparasitoses in
general) are often neglected by many health providers.
Hay et al. [5] summarize the current knowledge about
scabies in the developing world, with a focus on epidemiol-
ogy, transmission, pathogenesis, clinical manifestations, and
treatment. In some countries, the prevalence since 2004 has
ranged from 0.4% to 31%, overcrowding being the major fac-
tor in transmission. The major burden of scabies is second-
ary bacterial infection caused by group A streptococci and/
or Staphylococcus aureus, sometimes leading to nephritis,
rheumatic fever, and sepsis. The authors summarize the main
treatment options for scabies, 5% permethrin being the first-
line treatment and oral ivermectin being generally reserved
for recurrent difficult-to-treat scabies or crusted scabies. Tri-
als with good evidence are lacking [6], but Hay et al. [5] and
others [7] consider the use of ivermectin to be promising
for institutional outbreaks and mass administration in highly
endemic communities. Hopefully, in the near future, an Inter-
national Alliance for the Control of Scabies will give propos-
als and support to better control scabies in the developing
world.
Boyd and Reed [8] review the taxonomy of lice, given our
knowledge of approximately 4500 recognized species of
chewing lice and only 540 of sucking lice. The authors sum-
marize the data establishing the taxonomic rank of the
human body louse and the phylogenetic relationships of Phti-
rus and Pediculus. For instance, mitochondrial sequence data
have revealed human body lice to be eco-morphs of a single
species, which has challenged old concepts of the evolution-
ary history of parasitic lice. The authors outline the expected
and unexpected consequencies of sequencing the human
body louse genome. A fascinating section is devoted to en-
dosymbionts of lice, with bacteria being potentially engaged
in nutritional provisioning; new data obtained with molecular
tools involving supercomputers and metagenomic algorithms
have led to interesting discoveries in phylogenetic analysis.
Badiaga and Brouqui [9] review louse-borne infectious dis-
eases; in general, only body lice act as vectors for human
pathogens. The transmission of disease occurs through the
contamination of bite sites by faeces from infected body lice
or crushed infected louse bodies. It is of interest that, among
the three main diseases transmitted by body lice, two, epi-
demic typhus and trench fever, were detected in some
homeless populations. Moreover, Bartonella quintana was
found in head lice in schoolchildren from slums of resource-
poor countries but not in those in western countries. Inter-
estingly, experimental laboratory studies showed that the
body louse can transmit Acinetobacter baumanii and Yersinia
pestis. Indeed, as the authors emphasize, strict surveys,
improvements in hygienic conditions and efficient delousing,
with active antibiotics if necessary, should be carried out
with potential target populations.
Finally, Durand et al. [10] summarize what is known about
insecticide resistance in head lice. Clinical and parasitological
resistance in head lice was first described in France [11]
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from both a randomized controlled trial and ex vivo parasitol-
ogy test data. Resistance should be suspected when live lice
are still present on the head 24 h after application of insecti-
cide. Insecticide resistance has been described worldwide,
and is related to large insecticide selection pressure induced
by conventional pediculicides such as pyrethroids and mala-
thion. The molecular events that govern the resistance
include the recessive kdr trait linked to three point muta-
tions (M815I, T917I, and L920F) in the voltage-gated sodium
channel, which are responsible for a lower neurotoxic effect
of permethrin on lice. However, phenotype and genotype
are not strictly correlated. The authors also cover resistance
to malathion and lindane. Dealing with insecticide resistance
in head lice is not easy, and medical devices such as bug-
busting or dimeticone, or oral ivermectin [12] (not approved
in Europe), could be alternatives.
In conclusion, scabies and pediculosis affect most
countries in the world, developed or undeveloped, with the
potential involvement of a large number of individuals or
institutions. This special issue, giving an overview of scabies
and pediculosis, should provide an impetus for health author-
ities and physicans to be aware of these neglected diseases.
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